Please login to the form below

Not currently logged in
Email:
Password:

Zykadia

This page shows the latest Zykadia news and features for those working in and with pharma, biotech and healthcare.

Pfizer files third-gen ALK inhibitor for lung cancer

Pfizer files third-gen ALK inhibitor for lung cancer

Alecensa saw sales double to reach around $385m in 2017, and its ascendency also seems to have taken its toll on Novartis’second-generation drug Zykadia (ceritinib). ... After recording sales of $91m in 2016, Zykadia’s growth seems to have stalled

Latest news

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    That allows Roche’s drug to take on Pfizer’s drug - as well as Novartis’ALK inhibitor Zykadia (ceritinib) which was approved for first-line use in the US and Europe ... Of the two new challengers, Alecensa seems to be gaining ground the fastest,

  • Novartis gets first-line approval for Xalkori challenger in EU Novartis gets first-line approval for Xalkori challenger in EU

    Novartis gets first-line approval for Xalkori challenger in EU. Zykadia showed a 45% reduction in the risk of disease progression compared to chemo. ... Novartis won US approval for first-line use of Zykadia on the back of those trial data last month.

  • Novartis' Zykadia claims US approval for first-line lung cancer Novartis' Zykadia claims US approval for first-line lung cancer

    Novartis' Zykadia claims US approval for first-line lung cancer. The Swiss pharma giant’s drug also receives CHMP positive opinion. ... The FDA has said Novartis' Zykadia can be used as a first-line treatment option for some patients with non-small

  • Novartis' Zykadia prepped to take on Xalkori in Europe Novartis' Zykadia prepped to take on Xalkori in Europe

    Novartis' Zykadia prepped to take on Xalkori in Europe. The Swiss pharma giant’s drug will treat ALK-positive NSCLC patients. ... More patients in Europe should be eligible for treatment with Novartis' Zykadia after the EMA's advisory committee backed

  • Takeda's gamble on Ariad pays off with Alunbrig approval Takeda's gamble on Ariad pays off with Alunbrig approval

    Alunbrig could have a tough time of it entering the second-line NSCLC market in direct competition with Novartis' Zykadia (ceritinib) and Roche's  Alecensa (alectinib), which were both approved in ... Sales of Zykadia and Alecensa were $91m and $182m

More from news
Approximately 12 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    The phase 1/2 studies will assess Novartis' Zykadia [ceritinib], INC 280 and EGF 816 in combination with BMS's PD-1 immune checkpoint inhibitor nivolumab [Opdivo]. ... Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics